| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥9.5B | ¥6.9B | +37.6% |
| Operating Income | ¥1.6B | ¥0.4B | +252.7% |
| Ordinary Income | ¥1.6B | ¥0.5B | +244.8% |
| Net Income | ¥1.3B | ¥0.3B | +311.8% |
| ROE | 7.5% | 1.9% | - |
FY2026 Q3 results demonstrated strong performance with revenue of 9.5B yen (YoY +37.6%), operating income of 1.6B yen (YoY +252.7%), ordinary income of 1.6B yen (YoY +244.8%), and net income of 1.3B yen (YoY +311.8%). The company achieved a gross profit margin of 45.4% and operating margin of 16.3%, representing substantial profitability improvement. Basic EPS reached 23.50 yen compared to 5.71 yen in the prior year, an increase of 311.6%. Total assets grew to 19.6B yen with equity of 17.6B yen, maintaining an equity ratio of 89.7%. Cash and deposits stood at 11.1B yen, providing strong liquidity coverage.
Revenue increased 37.6% YoY to 9.5B yen, driven by growth across the business portfolio. The Nano and Micro Technology segment generated 7.8B yen in revenue, representing the primary revenue contributor, while the Macro Technology segment contributed 1.7B yen. Cost of sales increased to 5.2B yen, yet the company maintained a robust gross profit margin of 45.4%, indicating effective cost management relative to revenue expansion. Selling, general and administrative expenses totaled 2.7B yen, representing 29.0% of revenue, which declined as a percentage of sales compared to the operating leverage implied by the profit growth rate exceeding revenue growth. Operating income expanded 252.7% to 1.6B yen, yielding an operating margin of 16.3%, a substantial improvement reflecting both scale benefits and operational efficiency gains.
Ordinary income of 1.6B yen aligned closely with operating income, indicating minimal impact from non-operating items. The non-operating net contribution approximated 30M yen, consisting primarily of interest income of 2M yen and other minor items. Income tax expense of 0.2B yen resulted in an effective tax rate of approximately 13%, contributing to net income of 1.3B yen. The alignment between operating and ordinary income, combined with the tax efficiency, supported net income growth of 311.8%. No extraordinary items such as impairment losses, asset disposals, or restructuring charges were reported for the period. This represents a revenue up, profit up pattern, with profit growth substantially outpacing revenue growth due to margin expansion and operating leverage effects.
The Nano and Micro Technology segment generated revenue of 7.8B yen, representing approximately 82% of total revenue and establishing this as the core business. The Macro Technology segment contributed 1.7B yen, accounting for roughly 18% of total revenue. Segment profit data presented in the footnotes indicates that segment profit corresponds to gross profit on the income statement. The Other business category, which includes pharmaceutical container inspection services but is not classified as a reportable segment, represents additional diversification in the portfolio. While segment-level operating income was not separately disclosed, the dominant scale of Nano and Micro Technology indicates this segment drives the majority of overall profitability. The concentration in Nano and Micro Technology presents both opportunity through focused resource allocation and risk through segment concentration.
[Profitability] ROE of 7.5% represents the return generated on shareholder equity, supported by a net profit margin of 14.0% and operating margin of 16.3%, both reflecting strong profitability improvement from the prior year's compressed margins. The gross profit margin of 45.4% demonstrates effective value capture, while the SG&A ratio of 29.0% indicates disciplined overhead management. [Cash Quality] Cash and deposits of 11.1B yen provide coverage of 5.8 times against short-term liabilities of 1.9B yen, indicating substantial liquidity reserves. [Investment Efficiency] Asset turnover of 0.48 times reflects moderate asset utilization, as the asset-intensive nature of the business requires significant capital deployment. Total assets of 19.6B yen support the 9.5B yen revenue base. [Financial Health] Equity ratio of 89.7% represents an extremely conservative capital structure with minimal financial leverage. Current ratio of 742.2% and debt-to-equity ratio of 0.11 times underscore strong financial stability and low financial risk exposure.
Cash and deposits increased to 11.1B yen, representing 56.5% of total assets and providing substantial liquidity cushion. The balance sheet reflects working capital expansion, with trade receivables declining 30.8% YoY to 1.1B yen, suggesting improved collection efficiency or changes in sales mix and timing. Conversely, inventories increased 91.5% to 0.4B yen in finished goods, alongside raw materials of 0.9B yen and work in process of 0.5B yen, indicating inventory buildup totaling approximately 1.8B yen. Trade payables of 0.5B yen represent manageable supplier credit utilization. The net increase in cash position, combined with receivables reduction and inventory increase, suggests that operating profit growth and working capital management contributed to cash accumulation, though inventory buildup partially offset cash generation. Property, plant and equipment of 4.9B yen represents the primary non-current asset category, reflecting manufacturing infrastructure investments. The minimal debt position of 1.9B yen in current liabilities and 0.1B yen in non-current liabilities indicates limited financing activity and reliance on internal cash generation.
Ordinary income of 1.6B yen compared to operating income of 1.6B yen shows a marginal non-operating net contribution of approximately 30M yen, representing less than 1% of revenue. Non-operating income components consist primarily of interest income of 2M yen and other minor items, indicating that nearly all earnings derive from core operations. The minimal gap between operating and ordinary income, combined with the absence of material equity method gains, foreign exchange impacts, or extraordinary items, supports high earnings quality assessment. The effective tax rate of approximately 13% on profit before tax of 1.6B yen appears lower than standard corporate rates, though specific tax credits or adjustments were not detailed. While cash flow statement data was not provided, the substantial cash balance exceeding net income by a multiple of 8.3 times suggests historical cash generation capability, and the reduction in receivables indicates cash collection efficiency improved during the period.
Full-year guidance projects revenue of 12.9B yen (YoY +26.1%), operating income of 1.6B yen (YoY +51.8%), ordinary income of 1.7B yen (YoY +51.5%), and net income of 1.1B yen (YoY +8.9%). Q3 cumulative results show revenue progress of 73.6% against full-year guidance, operating income progress of 96.9%, ordinary income progress of 93.5%, and net income progress of 121.8%. Revenue tracking slightly below the 75% standard for Q3 suggests modest Q4 acceleration may be needed, while operating and ordinary income have nearly achieved full-year targets, indicating stronger-than-planned profitability through Q3. Net income progress exceeding 100% reflects tax efficiency or other factors benefiting bottom-line results beyond the original forecast. The forecast assumes continued business momentum, though specific assumptions were noted as subject to change based on available information and reasonable premises at the time of publication. No guidance revision was announced this quarter, indicating management maintains confidence in achieving or exceeding the stated targets.
The company forecasts an annual dividend of 4.00 yen per share for the fiscal year. Based on forecasted net income of 1.1B yen and approximately 5.69 million shares outstanding, the payout ratio calculates to approximately 20.7% against full-year earnings guidance. Using actual Q3 net income of 1.3B yen annualized, the payout ratio would approximate 17.1%, representing a conservative distribution policy that prioritizes earnings retention for growth investment and financial stability. No share buyback activity was disclosed for the period. The dividend policy appears sustainable given the substantial cash reserves of 11.1B yen, minimal debt obligations, and strong cash generation profile evidenced by the balance sheet position.
Inventory accumulation risk emerges as days inventory outstanding reached 122 days with inventory increasing 91.5% YoY to approximately 1.8B yen across finished goods, raw materials, and work in process. This buildup may reflect production planning for anticipated demand, though prolonged inventory holding increases obsolescence risk, carrying costs, and working capital pressure. Revenue concentration risk exists with the Nano and Micro Technology segment representing approximately 82% of total revenue, creating dependency on this single segment's market dynamics, competitive position, and customer demand patterns. Working capital efficiency risk is evidenced by a cash conversion cycle of 133 days, as inventory days of 122 days combined with receivables days partially offset by payables days results in extended working capital lock-up that constrains return on invested capital and cash availability for other uses.
[Industry Position] (Reference - Proprietary Analysis)
Profitability: ROE 7.5% (Industry Median 5.8%), Operating Margin 16.3% (Industry Median 8.9%), Net Profit Margin 14.0% (Industry Median 6.5%). The company demonstrates above-median profitability metrics across all dimensions, with operating margin nearly double the industry median, indicating strong pricing power, operational efficiency, or favorable business mix compared to manufacturing sector peers.
Financial Health: Equity Ratio 89.7% (Industry Median 63.8%), Current Ratio 742.2% (Industry Median 287.0%). The company maintains substantially more conservative financial positioning than industry peers, with equity ratio exceeding the median by 26 percentage points and current ratio indicating exceptional liquidity reserves.
Efficiency: Asset Turnover 0.48 (Industry Median 0.56), Inventory Turnover 122 days (Industry Median 112 days). Asset utilization trails the industry median slightly, and inventory days exceed the median by 10 days, consistent with the identified inventory buildup and suggesting room for improvement in working capital efficiency.
Growth: Revenue Growth 37.6% (Industry Median 2.8%), EPS Growth 311.6% (Industry Median 9.0%). The company significantly outpaces industry growth rates in both revenue and earnings, positioning it in the top tier of manufacturing sector growth performance.
※ Industry: Manufacturing sector, Comparison: 2025-Q3 period, Source: Proprietary analysis
Strong profitability momentum with operating margin of 16.3% nearly double the manufacturing industry median of 8.9%, combined with revenue growth of 37.6% versus industry median of 2.8%, positions the company as a high-growth, high-margin player within the manufacturing sector. The substantial margin expansion from prior year levels, with operating income growing 252.7% while revenue grew 37.6%, demonstrates operating leverage benefits and suggests the business model is achieving scale efficiencies. Conservative financial structure with 89.7% equity ratio and 11.1B yen cash reserves provides substantial financial flexibility for strategic investments, acquisitions, or shareholder returns, though current payout ratio of approximately 20% indicates management prioritizes capital retention. Working capital efficiency deterioration evidenced by 122-day inventory cycle and 91.5% inventory increase warrants monitoring, as sustained inventory buildup could pressure cash flows and signal demand-supply imbalances or production planning challenges that may impact future margin sustainability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.